ClinicalTrials.gg
RecruitingNCT05726825EXCHANGE-2Updated Mar 13, 2025

Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock

An interventional study of Therapeutic Plasma Exchange (TPE) in Septic Shock, sponsored by Hannover Medical School. Recruiting at 25 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by Hannover Medical School · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
274
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Shock, Septic with a site in Germany — 7 open to participants now, 7 under way, none of them phase 3. Shock, Septic · Germany.

Planned enrollment
16th of 29
274 · median 277
Started
2025
with 1 other
No phase
14 of 56
1 open now
Registered
53rd of 56
by date
Lead sponsor
3 of 56
Hannover Medical School

Among the 56 studies in Shock, Septic with a site in Germany, this one is the 16th largest by planned enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, and was the 53rd registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

7 of the 56 studies in Shock, Septic with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Shock, Septic with a site in Germany, or all of them as a file.
02

Study summary

Randomized, prospective, multicenter, open-label, controlled, parallel-group interventional trial to test the adjunctive effect of therapeutic plasma exchange in patients with early septic shock.

Read the detailed description

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to an infection; in septic shock profound circulatory, cellular and metabolic abnormalities are associated with an even higher mortality. Sepsis is a major healthcare problem, affecting millions of individuals around the world each year. Its incidence appears to be rising, and the mortality caused by septic shock in Germany in 2015 remains extraordinarily high (58.8%). It is well known - from the pathophysiological point of view - that these patients do not die from their infection per se but rather from multiple organ failure caused by their own overwhelming host response. This fact is so fundamental that it has been implemented as a key part of the 2016 sepsis definition (SEPSIS-3). Despite tremendous efforts during the last decades, innovative approaches targeting this fundamental hallmark of the disease, thereby reducing organ dysfunction, are lacking. Undoubtedly, there is an unmet need to expand the current standard of care for these patients by a more specific intervention.

The investigators hypothesize that early Therapeutic Plasma Exchange (TPE) in the most severely ill individuals will dampen the injurious maladaptive host response by removing injurious mediators thereby limiting organ dysfunction. The potential impact of this trial is of immense clinical relevance as it evaluates a promising adjunctive treatment option for a patient cohort suffering from an extraordinary high mortality. A positive trial result could truly change the current standard of care (SOC) - that is mostly supportive - of septic shock patients. Of note, there is neither a patent nor a direct commercial interest in such a trial.

03

Conditions studied

  • Septic Shock

Keywords

  • Septic Shock
  • Sepsis
  • Multi-organ failure
  • Extracorporeal therapy
  • Plasmapheresis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • New onset of septic shock (\< 24 hrs), (SEPSIS-3 definition)
  • Norepinephrine (NE) dose ≥ 0.4 μg/kg/min ≥ 30 min OR NE ≥ 0.3 μg/kg/min + vasopressin (any dose)
  • Established vascular access suitable for plasma exchange independent of study inclusion (due to established indication of RRT, expected need for RRT within the next 48 hours or other medical reasons as assessed by treating physician team)

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 or > 80 years
  • Urogenital focus of infection
  • Pregnancy
  • Heparin-induced thrombocytopenia
  • Known reaction against fresh frozen plasma (FFP)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
274 participants (estimated)

Study arms

  • Experimental
    Therapeutic Plasma Exchange (TPE)

    1 x TPE with donor Fresh Frozen Plasma (FFPs) (1.2 x individual plasma volume) within the first 6 hrs after randomization. A second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min within 24 hours after the first intervention.

    Device: Therapeutic Plasma Exchange (TPE)

  • No intervention
    Standard of Care (SOC)

    Non-interventional standard of care

Interventions

  • DeviceTherapeutic Plasma Exchange (TPE)

    The TPE treatment will be initiated within 6 hrs after randomization. Duration of TPE treatment is approximately 120-180 minutes. An additional second TPE can be performed if the patient remains vasopressor dependent ≥ 0.4 ug/kg/min after 24 hours following the first TPE procedure. Both unfractionated heparin (UFH) and citrate may be used as anticoagulant medication. To ensure treatment comparability between different patients, we will replace plasma in a fixed ratio of 1.2 x the individual patient's total plasma fluid.

06

What researchers measure

Primary outcomes

  1. 28-day mortality

    Time frame: from randomization up to 28 days following randomization

Secondary outcomes

  1. Mean daily Sequential Organ Failure Score (SOFA) score over the first 7 days (KEY secondary outcome)

    Per-patient mean daily SOFA score over the first 7 days, ranging from 0-24 points with higher scores indicating more severe organ dysfunction

    Time frame: from randomization up to 7 days following randomization

  2. Organ support free days until day 28 (KEY secondary outcome)

    total days free of invasive ventilation, vasopressors/inotrops and renal replacement therapy (RRT) until day 28

    Time frame: from randomization up to 28 days following randomization

  3. 90-day mortality

    Time frame: from randomization up to 90 days following randomization

  4. Intensive Care unit (ICU) length of stay

    total days in ICU

    Time frame: from randomization until ICU discharge

  5. Hospital length of stay

    total days in hospital

    Time frame: from randomization until hospital discharge

  6. Basic Hemodynamics

    includes: Norepinephrine- \[µg/kg/min\], Dobutamine \[µg/kg/min\], Epinephrine- \[µg/kg/min\] and Vasopressin-dose \[U/kg/min\], Vasocative-inotropic (VIS) Score with higher scores indicating higher vasopressor/inotropic support, Mean arterial pressure (MAP, \[mmHg\]), Heart Rate (HR, \[1/min\]), Central venous pressure (CVP, \[mmHg\]) and Central-Venous Oxygen Saturation (ScvO2, \[%\]) at 0 and 12 hrs, d1-7

    Time frame: at days 1-7 following randomization

  7. Extended Hemodynamics

    includes: Cardiac Index (CI, \[l/min/m2\]), Global End-Diastolic Volume Index (GEDI, \[ml/m2\]), Sytemic Vascular Resistance Index (SVRI, \[dyn\*s\*cm-5\*m2\]), Stroke Volume Variation (SVV, \[%\] ), Extravascular Lung Water Index (ELWI, \[ml/kg\]) and Pulmonar Vascular Permeability Index (PVPI) at at 0 and 12 hrs, d1-7

    Time frame: at days 1-7 following randomization

  8. Arterial blood gas analysis

    includes: pH, PCO2 \[mmHg\], HCO3- \[mmol\], PO2 \[mmHg\], Lactate \[mmol/l\] at 0 and 12 hrs, d1-7

    Time frame: at days 1-7 following randomization

  9. Respiratory function

    includes: pO2/FiO2, Tidal Volume (VT, \[ml\]), Positive End-Exspiratory Pressure (PEEP, \[cmH2O\]), Peak-Pressure (Ppeak, \[cmH2O\]), Plateau-Pressure (Pplat, \[cmH2O\]), Respiratory Rate (RR, \[1/min\]), Inspiratory Time (Tinsp, \[s\]), Inspiratory-Flow and End-tidal-CO2 (etCO2, \[mmHg\]) at 0 and 12 hrs, d1-7

    Time frame: at days 1-7 following randomization

  10. Renal function

    includes: Presence of Acute kindey injury (AKI), AKI stage (KDIGO definition) stage 1-3 with higher stage indicating worse renal function, Need for Renal Replacement Therapy (RRT), Estimated Glomerular Filtration Rate (eGFR following CKD-EPI equation) \[ml/min\], Fluid intake \[ml/d\], Urine output \[ml/d\], Ultrafiltration and Net daily fluid balance \[ml/d\] at 0 and 12 hrs, d1-7 and at ICU discharge

    Time frame: at days 1-7 following randomization and at ICU discharge

  11. Liver Function

    includes: Bilirubin, Aspartate aminotransferase (AST, \[U/l\]), Alanine aminotransferase (ALT, \[U/l\]), Alkaline phosphatase (AP, \[U/l\]), Gamma-glutamyl transferase (GGT, \[U/l\]), Cholinesterase (CHE, \[kU/l\]) and Albumin \[g/l\] at 0 and 12 hrs, d1-7 and at ICU discharge

    Time frame: at days 1-7 following randomization and at ICU discharge

  12. Sepsis associated coagulopathy

    includes: Differential blood count including schistocytes \[%\], Fibrinogen \[g/l\] , D-Dimer \[mg/l\], International Normalized Ratio (INR), Lactate dehydrogenase (LDH, \[U/l\]), Antithrombin-III (AT-III, \[%\]), Protein C \[%\] and International Society on Thrombosis and Hemostasis- Disseminated Intravscular Coagulation Score (ISTH-DIC, \[U/l\]) ranging from 0-8 points with higher values indication more severe DIC at 0 and 12 hrs, d1-7, A disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13, \[%\]) and von-Willebrand-Factor Antigen (vWF:Ag,\[IU/l\]) at 0 and 24 hrs

    Time frame: at days 1-7 following randomization

  13. Inflammatory response

    includes: C-reactive protein (CRP, \[mg/l\]), Procalcitonin (PCT, \[ug/l\]), Interleukin-6 (IL-6, \[ng/ml\]), Ferritin \[ug/l\] and Neutrophil/Lymphocyte ratio at 0 and 12 hrs, d1-7

    Time frame: at days 1-7 following randomization

  14. Cardiac function

    includes: Creatine kinase (CK, \[U/l\]), Myoglobin \[ug/l\], Troponin T \[ng/l\], NT-proBNP \[ng/l\] at 0 and 12 hrs, d1-7 and at ICU discharge

    Time frame: at days 1-7 following randomization and at ICU discharge

  15. Secondary infections

    includes: incidence and type of secondary infections until ICU and hospital discharge, incidence of viral (HSV, EBV, CMV) reactivation at d7 and d14

    Time frame: from randomization until hospital discharge

Other outcomes

  1. Safety Endpoints

    includes: Incidence of bleeding, allergic reactions, Transfusion associated lung injury (TRALI), severe thrombocytopenia (\< 5000/µl) and (other) severe adverse events (SAEs)

    Time frame: from randomization until day 7 following randomization

07

Study locations

3 of 25 sites recruiting
08

References and documents

Publications

  • Knaup H, Stahl K, Schmidt BMW, Idowu TO, Busch M, Wiesner O, Welte T, Haller H, Kielstein JT, Hoeper MM, David S. Early therapeutic plasma exchange in septic shock: a prospective open-label nonrandomized pilot study focusing on safety, hemodynamics, vascular barrier function, and biologic markers. Crit Care. 2018 Oct 30;22(1):285. doi: 10.1186/s13054-018-2220-9. PubMed 30373638 ↗
  • Stahl K, Schmidt JJ, Seeliger B, Schmidt BMW, Welte T, Haller H, Hoeper MM, Budde U, Bode C, David S. Effect of therapeutic plasma exchange on endothelial activation and coagulation-related parameters in septic shock. Crit Care. 2020 Mar 2;24(1):71. doi: 10.1186/s13054-020-2799-5. PubMed 32122366 ↗
  • Stahl K, Bikker R, Seeliger B, Schmidt JJ, Schenk H, Schmidt BMW, Welte T, Haller H, Hoeper MM, Brand K, David S. Effect of Therapeutic Plasma Exchange on Immunoglobulin Deficiency in Early and Severe Septic Shock. J Intensive Care Med. 2021 Dec;36(12):1491-1497. doi: 10.1177/0885066620965169. Epub 2020 Oct 16. PubMed 33063613 ↗
  • David S, Bode C, Putensen C, Welte T, Stahl K; EXCHANGE study group. Adjuvant therapeutic plasma exchange in septic shock. Intensive Care Med. 2021 Mar;47(3):352-354. doi: 10.1007/s00134-020-06339-1. Epub 2021 Jan 20. No abstract available. PubMed 33471132 ↗
  • Stahl K, Hillebrand UC, Kiyan Y, Seeliger B, Schmidt JJ, Schenk H, Pape T, Schmidt BMW, Welte T, Hoeper MM, Sauer A, Wygrecka M, Bode C, Wedemeyer H, Haller H, David S. Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock. Intensive Care Med Exp. 2021 Nov 24;9(1):57. doi: 10.1186/s40635-021-00417-4. PubMed 34817751 ↗
  • Stahl K, Wand P, Seeliger B, Wendel-Garcia PD, Schmidt JJ, Schmidt BMW, Sauer A, Lehmann F, Budde U, Busch M, Wiesner O, Welte T, Haller H, Wedemeyer H, Putensen C, Hoeper MM, Bode C, David S. Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial. Crit Care. 2022 May 12;26(1):134. doi: 10.1186/s13054-022-04003-2. PubMed 35551628 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2028, 36 months after the start.

Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 36 months is above that.

Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2023
First posted
Feb 14, 2023
StartActual
Feb 19, 2025
Primary completionEst.
Feb 2028
CompletionEst.
Apr 2028
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05726825
Responsible party
Sponsor
First posted
Feb 14, 2023
Start date
Feb 19, 2025
Primary completion
Feb 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
Mar 13, 2025

Study contacts

Sascha David, Prof. Dr.
Contact
sascha.david@usz.ch
+41 44 255 8653
Klaus Stahl, PD Dr.
Contact
stahl.klaus@mh-hannover.de
+49 (0)176 1532 8277
Sascha David, Prof. Dr.
principal investigator · University of Zurich
Klaus Stahl, PD Dr.
principal investigator · Hannover Medical School
Christian Bode, PD Dr.
principal investigator · University Hospital, Bonn

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion